Trade PURETECH HEALTH PLC ORD 1P - PRTC CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.0120 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023925% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.002007% | ||||||||
| Overnight fee time | 22:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | GBP | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United Kingdom of Great Britain and Northern Ireland | ||||||||
| Commission on trade | 0% |
| Prev. Close | 1.622 |
| Open | 1.62 |
| 1-Year Change | -2.09% |
| Day's Range | 1.62 - 1.642 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Nov 21, 2024 | 1.6220 | 0.0140 | 0.87% | 1.6080 | 1.6220 | 1.5840 |
| Nov 20, 2024 | 1.6080 | -0.0120 | -0.74% | 1.6200 | 1.6340 | 1.5640 |
| Nov 19, 2024 | 1.6200 | -0.0260 | -1.58% | 1.6460 | 1.6500 | 1.5940 |
| Nov 18, 2024 | 1.6280 | -0.0560 | -3.33% | 1.6840 | 1.6860 | 1.5980 |
| Nov 15, 2024 | 1.7080 | -0.0220 | -1.27% | 1.7300 | 1.7500 | 1.7000 |
| Nov 14, 2024 | 1.7280 | 0.0520 | 3.10% | 1.6760 | 1.7280 | 1.6400 |
| Nov 13, 2024 | 1.6860 | -0.0120 | -0.71% | 1.6980 | 1.7280 | 1.6160 |
| Nov 12, 2024 | 1.7280 | 0.0800 | 4.85% | 1.6480 | 1.7420 | 1.6180 |
| Nov 11, 2024 | 1.6940 | 0.1540 | 10.00% | 1.5400 | 1.7000 | 1.5260 |
| Nov 8, 2024 | 1.5400 | -0.0020 | -0.13% | 1.5420 | 1.5580 | 1.5140 |
| Nov 7, 2024 | 1.5360 | -0.0200 | -1.29% | 1.5560 | 1.5660 | 1.5260 |
| Nov 6, 2024 | 1.5480 | 0.0000 | 0.00% | 1.5480 | 1.5900 | 1.5380 |
| Nov 5, 2024 | 1.5480 | 0.0000 | 0.00% | 1.5480 | 1.6000 | 1.5440 |
| Nov 4, 2024 | 1.6000 | 0.0740 | 4.85% | 1.5260 | 1.6220 | 1.5260 |
| Nov 1, 2024 | 1.5680 | 0.0420 | 2.75% | 1.5260 | 1.5740 | 1.5240 |
| Oct 31, 2024 | 1.5280 | -0.0340 | -2.18% | 1.5620 | 1.5720 | 1.5120 |
| Oct 30, 2024 | 1.5660 | 0.0160 | 1.03% | 1.5500 | 1.6160 | 1.5380 |
| Oct 29, 2024 | 1.5500 | 0.0500 | 3.33% | 1.5000 | 1.5620 | 1.5000 |
| Oct 28, 2024 | 1.5280 | 0.0220 | 1.46% | 1.5060 | 1.5300 | 1.5020 |
| Oct 25, 2024 | 1.5080 | -0.0160 | -1.05% | 1.5240 | 1.5260 | 1.4825 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Puretech Health plc Company profile
PureTech Health plc, a clinical-stage biopharma company, focuses on developing medicines targeting serious diseases that result from dysfunctions in the nervous, immune, and gastrointestinal systems. The company is developing a digital medicine platform for the treatment and assessment of cognitive dysfunction across various neurological and psychiatric indications; therapies to treat a range of acute and chronic inflammatory disorders; microbiome-derived immune modulators for maternal and paediatric health; novel approach to oral delivery of biologics, vaccines, and other drugs; platform to address androgenetic alopecia; mechanotherapeutics to treat obesity, and other chronic diseases related to the gastrointestinal pathway; muscarinic receptor agonist programme for the treatment of psychosis and cognition, including schizophrenia and Alzheimer''s; monoclonal antibody-based therapeutic to treat pancreatic cancer and other solid tumors; voice-based technology platform for monitoring and diagnosing mental and physical medical conditions, such as depression, Alzheimer''s disease, multiple sclerosis, and Parkinson''s disease; platform and products that seek to explore and leverage the health potential of music; therapies for immune-mediated and infectious diseases based on rationally-defined consortium of human microbiome-derived bacteria; and novel antibody and cell therapies for treating cancer. It is also developing a milk exosome-based technology designed to enable the oral administration of biologics, nucleic acids, and complex small molecules; and a lipid prodrug technology to enable lymphatic targeting. In addition, the company''s medical device programme is developing a non-invasive neurostimulation treatment for psychiatric disorders, including depression and bipolar disorder. PureTech Health plc was incorporated in 2015 and is headquartered in Boston, Massachusetts.| Industry: | Biotechnology & Medical Research (NEC) |
6 Tide Street
Suite 400
BOSTON
MASSACHUSETTS 02210
US
News
Gold price predictions for the next five years: Third party data round up
Explore the future of gold prices and whether the yellow metal will continue its upward trend in the coming years.
15:17, 18 November 2024
Shiba Inu coin price prediction 2030: could Shiba Inu coin reach $1? Third party price target
Can Shiba Inu reinvent itself to become a worthy long-term investment?
08:36, 15 November 2024
Trump trades charge as Bitcoin hits $US80,000
Bitcoin hits $80,000 amid expectations of fiscal stimulus, lower regulatory risks, and resilient US economy.
10:48, 13 November 2024
Australian jobs data expected to point to solid labour market conditions
Australian labour market and wage data to reveal job growth resilience, shaping RBA rate cut expectations and impacting AUD amidst global economic shifts.
10:16, 13 November 2024
FOMC cuts interest rates as expected and sticks to its line on future policy
The FOMC cut interest rates by 25 basis points at its November meeting, aligning with expectations. Wall Street hit record highs following the decision, with tech stocks leading the rally. Markets are pricing in a probable December cut amid resilient economic indicators.
13:33, 8 November 2024
FOMC and BOE preview: further rate cuts expected
Both the Federal Reserve and the Bank of England are expected to cut rates further when they meet later this week.
14:14, 5 November 2024
RBA meeting preview: No change to policy expected as inflation fight continues
The Reserve Bank of Australia is expected to keep its cash rate on hold at 4.35% when it announces its policy decision at 2.30PM on the 5th of November, 2024. Despite ongoing evidence of soft demand, upside risks to inflation are likely to remain the central bank’s primary concern.
13:35, 4 November 2024People also watch
Still looking for a broker you can trust?
Join the 660,000+ traders worldwide that chose to trade with Capital.com